Immunotherapies for emergency situations

Treatments for biodefence solutions and emerging infectious diseases

Fabentech specialises in the development and production of emergency treatments to fight the highest-priority biological threats to public health.

FabShield®: Unique polyclonal antibody technology platform

Our validated FabShield® technology platform relies on the production of highly purified polyclonal antibodies fragments. These antibodies specifically recognise, then neutralise, the virus or toxin and their variants to put a halt to the development of the disease or poisoning.

Medical countermeasures for public health crises

Fabentech’s mission is to provide effective treatments to cope with public health emergencies and to support global health security. We strive to create innovative solutions to ensure rapid response to potential pandemics or bioterror attacks

Our pipeline

Fabentech’s portfolio comprises a broad scope of life-saving solutions designed to neutralise the most critical viruses and biological toxins.

Indication Proof of concept Preclinical stage Clinical stage Development completed

Toxins

Antidote #1 - BIODEFENCE

Antidote #2 - BIODEFENCE

Antidote #3 - BIODEFENCE

Viruses

FabenFLU® - H5N1

FabenCOV® - COVID-19

NIPAH

e-FabRIC - SARBECOVIRUS

Newsroom

Fabentech announces the launch and first results of first-in-human clinical trial evaluating the safety of its antidote against a deadly plant-based toxin of bioterrorism interest.

Fabentech

Fabentech awarded €7.7m from the European Commission as coordinator of the e FabRIC consortium to develop an innovative broad-spectrum therapy against emerging viruses with pandemic potential

news1

Fabentech’s polyclonal antibody technology chosen by the European Commission to counter CBRN threats within the framework of the Counteract consortium